Akouos IPO Presentation Deck

Planned AK-OTOF Phase 1/2 Clinical Trial 31 Part A Dose Escalation Assess: Safety, tolerability, and bioactivity Key Eligibility Administration Efficacy Endpoints Timing Up to 5-year clinical follow-up Individuals with OTOF-mediated hearing loss • Amenable to surgical delivery and potential for benefit • May enroll children as young as one year old in the expansion phase (¹) Part B Cohort Expansion Assess: Safety and effectiveness Administered to trial participants through a single unilateral intracochlear injection • Objective and clinically relevant ABR testing and age appropriate behavioral assessment (1) Based on pre-IND meeting with FDA in September 2019. Submit IND in 2021 • Intend to file the delivery device along with the investigational product as a combination product(¹) CONFIDENTIAL AKQUOS

View entire presentation